Cas no 102625-70-7 (Pantoprazole)
Pantoprazole Chemical and Physical Properties
Names and Identifiers
-
- Pantoprazole
- 5-(DIFLUOROMETHOXY)-2-[[(3,4-DIMETHOXY-2-PYRIDINYL)METHYL]SULFINYL]-1H-BENZIMIDAZOLE
- 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1h-benzimidazole
- Pantoprazole&
- Int.
- 5-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-3H-benzoimidazole
- (3,4-dimethoxy-2-pyridinyl)methyl 5-methyl-1H-1,3-benzimidazol-2-yl sulfoxide
- BY-1023
- SKF-96022
- [(3,4-Dimethoxypyridin-2-yl)methyl][5-(difluoromethoxy)-1H-benzimidazol-2-yl] sulfoxide
- 5-(Difluoromethoxy)-1H-benzimidazole-2-yl(3,4-dimethoxy-2-pyridylmethyl) sulfoxide
- Pantoprazole sodium
- SKF96022
- [14C]-Pantoprazole
- 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyriainyl)methyl]sulfinyl]-1H-benzimidazole
- 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole
- 5-difluorom
- 5-difluoromethoxy-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
- 5-difluoromethoxy-2-[(3,4-dimethoxy-pyridin-2-yl)methylsulfinyl]-1H-benzimidazole
- Pantoloc
- Pantoprazol
- Pantoprazolum
- Pantoprazolum [INN-Latin]
- Pantozol
- Patoprazole
- Protonix
- Pantoprazole&Int.
- Pantoprazole (Protonix)
- PANTOPRAZOLE SODIUM 98-102%
- Pantoprazole (base and/or unspecified salts)
- 5-(difluoMethoxyl)-2-{[(3,4-diMethoxyl-2-pyridy
- Tox21_111477_1
- BRD-A22380646-001-01-5
- (R)-(+)-Pantoprazole;(+)-(R)-Pantoprazole;Pantoprazole Isomer(R) Impurity
- MFCD00870182
- Pantoprazole (USAN/INN)
- 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)
- (R)-6-(Difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
- Pantecta Control
- Pantoprazol [INN-Spanish]
- (+)-(R)-Pantoprazole
- NSC-759257
- CS-3161
- FT-0602547
- DTXCID803416
- Panyocid
- D05353
- Pantoprazole [USAN:INN:BAN]
- EN300-19767202
- BY1023
- SR-01000763715
- PANTOPRAZOLE [HSDB]
- MLS003882559
- PANTOPRAZOLE [MI]
- PANTOPRAZOLE [VANDF]
- NSC759257
- 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-1h-benzimidazole
- DTXSID4023416
- NCGC00095188-02
- Pantozol Control
- apo-Pantoprazole
- SCHEMBL29465
- DB00213
- BRD-A22380646-001-02-3
- NCGC00095188-04
- BCP21400
- 6-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole
- NCGC00095188-03
- (R)-(+)-Pantoprazole;R-enantiomer of Pantoprazole;(R)-Pantoprazole;5-(Difluoromethoxy)-2-[(R)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole ;5-(Difluoromethoxy)-2-[(R)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole. - See more at: https://www.clearsynth.com/en/CST38666.html#sthash.yGNPTXpx.dpuf
- (R)-Pantoprazole
- NCGC00095188-01
- HSDB 7292
- Altopan
- PANTOPRAZOLE (MART.)
- SBI-0206873.P001
- CHEBI:7915
- A901011
- Controloc Control
- SMR002533625
- CCG-268437
- SK&F-96022
- 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-
- BS-14224
- GTPL7260
- EC 600-331-6
- 5-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
- D8TST4O562
- 164579-32-2
- PANTOPRAZOLE [WHO-DD]
- s2105
- BDBM50241342
- PANTOPRAZOLE [MART.]
- (S)-Pantoprazole
- 1H-BENZIMIDAZOLE, 5-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDYL)METHYL)SULFINYL)-
- CHEMBL1502
- BCP20279
- Somac Control
- HMS1922H20
- AKOS034831879
- Pantoloc Control
- AKOS015894910
- Q286846
- AB01275513_02
- 5-Difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
- 5-(Difluoromethoxy)-2-
- 2-(((3,4-DIMETHOXYPYRIDIN-2-YL)METHYL)SULFINYL)-5-DIFLUOROMETHOXY-1H-BENZIMIDAZOLE
- AB01275513-01
- SK&F 96022
- SPECTRUM1505818
- AC-679
- 5-(difluoromethoxy)-2-{[(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole
- SR-01000763715-3
- 6-(DIFLUOROMETHOXY)-2-(((3,4-DIMETHOXY-2-PYRIDINYL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE
- NSC 759257
- 5-(difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1H-benzimidazole
- CAS-102625-70-7
- PANTOPRAZOLE [EMA EPAR]
- P2262
- BY 1023
- NCGC00095188-05
- PANTOPRAZOLE [USAN]
- PANTOPRAZOLE [INN]
- Zovanta
- (+/-)-PANTOPRAZOLE
- Pharmakon1600-01505818
- 5-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole
- NS00000297
- 102625-70-7
- Pantoprazol (INN-Spanish)
- BSPBio_002320
- 6-(difluoromethoxy)-2-((3,4-dimethoxypyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole
- 6-(difluoromethoxy)-2-[(3,4-dimethoxy-2-pyridyl)methylsulfinyl]-1H-benzimidazole
- BIDD:GT0003
- HMS2093F14
- A02BC02
- 5-(Difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridyl)methyl)sulfinyl)benzimidazole
- 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole
- 5-Difluoromethoxy-2-(3,4-dimethoxy-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole
- A800593
- 2-(((3,4-Dimethoxy-2-pyridinyl)methyl)-sulfinyl)-5-methyl-1H-1,3-benzimidazole
- UNII-D8TST4O562
- J-000744
- 5-(Difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl]benzimidazole
- CCG-213558
- (S)-6-(Difluoromethoxy)-2-(((3,4-dimethoxypyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
- HY-17507
- Tox21_111477
- Pantoprazole sodium hydrate
- Protonix I.V.
- HMS2090H03
- 6-(difluoromethoxy)-2-[(3,4-dimethoxypyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
- Pantoprazolum (INN-Latin)
- SB17368
- NCGC00389443-01
- SK-96022
- BRD-A22380646-236-06-6
- G60931
- STL451032
- BRD-A22380646-001-05-6
- BRD-A22380646-236-05-8
- NCGC00095188-08
-
- MDL: MFCD00870182
- Inchi: 1S/C16H15F2N3O4S/c1-23-13-5-6-19-12(14(13)24-2)8-26(22)16-20-10-4-3-9(25-15(17)18)7-11(10)21-16/h3-7,15H,8H2,1-2H3,(H,20,21)
- InChI Key: IQPSEEYGBUAQFF-UHFFFAOYSA-N
- SMILES: S(CC1C(=C(C=CN=1)OC)OC)(C1=NC2C=CC(=CC=2N1)OC(F)F)=O
Computed Properties
- Exact Mass: 383.07500
- Monoisotopic Mass: 383.075133
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 1
- Hydrogen Bond Acceptor Count: 7
- Heavy Atom Count: 26
- Rotatable Bond Count: 7
- Complexity: 490
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 0
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Topological Polar Surface Area: 106
- Surface Charge: 0
- Tautomer Count: 2
- XLogP3: 2.4
Experimental Properties
- Color/Form: Quasi white solid
- Density: 1.51
- Melting Point: 139-140° (dec)
- Boiling Point: 586.9 °C at 760 mmHg
- Flash Point: 308.7 °C
- Refractive Index: 1.642
- PSA: 105.54000
- LogP: 3.75000
- pka: pKa1 3.92; pKa2 8.19(at 25℃)
Pantoprazole Security Information
- Hazardous Material transportation number:UN 3265 8/PG 2
- WGK Germany:3
- Hazard Category Code: R41: risk of serious eye damage. R48: risk of serious health damage due to long-term exposure. R20/21/22: harmful by inhalation, skin contact and accidental swallowing. R37/38: irritating to respiratory tract and skin.
- Safety Instruction: S26-S36/37/39-S45
-
Hazardous Material Identification:
- Safety Term:8
- Packing Group:III
- Risk Phrases:R20/21/22
- Packing Group:III
- Hazard Level:8
- Storage Condition:Please store the product under the recommended conditions in the Certificate of Analysis.
Pantoprazole Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| S e l l e c k ZHONG GUO | S2105-100mg |
Pantoprazole |
102625-70-7 | 99.94% | 100mg |
¥794.97 | 2023-09-15 | |
| S e l l e c k ZHONG GUO | S2105-500mg |
Pantoprazole |
102625-70-7 | 99.94% | 500mg |
¥2433.32 | 2023-09-15 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | P302094-1g |
Pantoprazole |
102625-70-7 | 97% | 1g |
¥871.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | P302094-100mg |
Pantoprazole |
102625-70-7 | 97% | 100mg |
¥435.00 | 2021-05-25 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | P302094-5g |
Pantoprazole |
102625-70-7 | 97% | 5g |
¥3136.90 | 2023-09-01 | |
| SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd. | P302094-500mg |
Pantoprazole |
102625-70-7 | 97% | 500mg |
¥1,327.00 | 2021-05-25 | |
| DC Chemicals | DC9876-100 mg |
Pantoprazole |
102625-70-7 | >98% | 100mg |
$100.0 | 2022-02-28 | |
| DC Chemicals | DC9876-250 mg |
Pantoprazole |
102625-70-7 | >98% | 250mg |
$200.0 | 2022-02-28 | |
| DC Chemicals | DC9876-1 g |
Pantoprazole |
102625-70-7 | >98% | 1g |
$400.0 | 2022-02-28 | |
| TRC | P190003-100mg |
Pantoprazole |
102625-70-7 | 100mg |
$ 52.00 | 2023-09-06 |
Pantoprazole Suppliers
Pantoprazole Related Literature
-
M. Shukla,M. Y. Malik,S. Jaiswal,A. Sharma,D. K. Tanpula,R. Goyani,J. Lal RSC Adv. 2016 6 58933
-
Yan Dai,Bing-Liang Ma,Min Zheng,Rong Shi,Yuan-Yuan Li,Tian-Ming Wang,Yue-Ming Ma RSC Adv. 2017 7 15236
-
Barbara Kasprzyk-Hordern Chem. Soc. Rev. 2010 39 4466
-
Barbara Kasprzyk-Hordern Chem. Soc. Rev. 2010 39 4466
-
Majid M. Heravi,Vahideh Zadsirjan RSC Adv. 2020 10 44247
Additional information on Pantoprazole
Recent Advances in Pantoprazole (102625-70-7) Research: A Comprehensive Review
Pantoprazole (CAS: 102625-70-7), a proton pump inhibitor (PPI), has been widely used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Recent studies have focused on its pharmacological mechanisms, clinical efficacy, and potential new applications. This review synthesizes the latest findings from peer-reviewed journals, clinical trials, and industry reports to provide a comprehensive update on Pantoprazole research.
One of the key areas of recent investigation is the molecular mechanism of Pantoprazole's action. Studies have elucidated its binding affinity to the H+/K+-ATPase enzyme in gastric parietal cells, leading to prolonged inhibition of gastric acid secretion. Advanced crystallography and molecular docking simulations have provided deeper insights into the structural interactions between Pantoprazole and its target, which may inform the development of next-generation PPIs with improved efficacy and reduced side effects.
Clinical research has also explored the comparative effectiveness of Pantoprazole versus other PPIs. A 2023 meta-analysis of randomized controlled trials demonstrated that Pantoprazole exhibits comparable efficacy to omeprazole and esomeprazole in acid suppression but with a more favorable safety profile, particularly in long-term use. These findings support its continued preference in specific patient populations, such as the elderly and those with renal impairment.
Emerging applications of Pantoprazole beyond its traditional uses have been a significant focus. Preclinical studies suggest potential anti-inflammatory and antioxidant properties, which could expand its therapeutic scope. For instance, recent in vitro and animal models indicate that Pantoprazole may modulate cytokine production and reduce oxidative stress, opening avenues for research in conditions like inflammatory bowel disease and even certain cancers.
Pharmacokinetic studies have further refined our understanding of Pantoprazole's metabolism, particularly the role of CYP2C19 polymorphisms in its variability among individuals. New formulations, including delayed-release tablets and intravenous preparations, have been developed to enhance bioavailability and patient compliance, addressing some of the limitations observed in earlier versions of the drug.
In conclusion, Pantoprazole (102625-70-7) remains a cornerstone in acid-related disorder management, with ongoing research uncovering new dimensions of its pharmacology and therapeutic potential. Future directions may include personalized medicine approaches based on genetic profiling and the exploration of its pleiotropic effects in non-GI indications. This evolving body of knowledge underscores the importance of continued investment in Pantoprazole-related research to optimize its clinical utility.
102625-70-7 (Pantoprazole) Related Products
- 118-71-8(Maltol)
- 142678-35-1(1H-Benzimidazole,5-(difluoromethoxy)-2-[(S)-[(3,4-dimethoxy-2-pyridinyl)methyl]sulfinyl]-)
- 142706-18-1((R)-(+)-Pantoprazole)
- 138786-67-1(Pantoprazole Sodium)
- 102625-64-9(Pantoprazole sulfide)
- 1205-30-7(4-Chloro-3-sulfamoylbenzoic acid)
- 92806-98-9(2-sulfanyl-1H-1,3-benzodiazol-6-ol)
- 22236-11-9(4'-(Difluoromethoxy)acetanilide)
- 103-90-2(Acetaminophen)
- 127780-16-9(Pantoprazole Sulfone)